Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Retained Earnings: 2023-2025

Historic Retained Earnings for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to -$337.7 million.

  • CG Oncology's Retained Earnings fell 81.36% to -$337.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$337.7 million, marking a year-over-year decrease of 81.36%. This contributed to the annual value of -$218.0 million for FY2024, which is 67.75% down from last year.
  • CG Oncology's Retained Earnings amounted to -$337.7 million in Q3 2025, which was down 14.90% from -$293.9 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Retained Earnings ranged from a high of -$129.9 million in Q4 2023 and a low of -$337.7 million during Q3 2025.
  • Over the past 3 years, CG Oncology's median Retained Earnings value was -$202.1 million (recorded in 2024), while the average stood at -$216.4 million.
  • Data for CG Oncology's Retained Earnings shows a maximum YoY slumped of 81.36% (in 2025) over the last 5 years.
  • CG Oncology's Retained Earnings (Quarterly) stood at -$129.9 million in 2023, then crashed by 67.75% to -$218.0 million in 2024, then plummeted by 81.36% to -$337.7 million in 2025.
  • Its last three reported values are -$337.7 million in Q3 2025, -$293.9 million for Q2 2025, and -$252.4 million during Q1 2025.